Background Tenofovir alafenamide (TAF) is a new anti-hepatitis B virus nucleotide analogue
that can cause dyslipidaemia in AIDS patients, but the effect of TAF on blood lipids in …

BACKGROUND Tenofovir alafenamide (TAF) has a serum lipid-raising effect in patients with
HIV; however, its effect on serum lipids and nonalcoholic fatty liver disease (NAFLD) risk in …

Background Concerns have been raised regarding changes in lipid profiles among patients
with chronic hepatitis B (CHB) during tenofovir alafenamide fumarate (TAF) treatment. We …

This study aimed to compare the serum lipid profiles between tenofovir disoproxil fumarate
(TDF) and tenofovir alafenamide (TAF) in the long-term treatment of chronic hepatitis B …

Background This study was aimed at investigating the dynamics of lipids and the effect of
TAF on the lipid profile of patients including fatty liver disease in CHB patients. Methods The …

Background The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and
other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B …

Background/Aims Tenofovir alafenamide (TAF) has shown less favorable effect on lipids
compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding …

INTRODUCTION: Tenofovir disoproxil fumarate (TDF) has commonly been replaced by
tenofovir alafenamide (TAF) because of better kidney and bone safety. However clinical …

Background Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are first‐line
treatments for chronic hepatitis B (CHB). Studies suggest lipid lowering effect of TDF in …

Background and Aims The effect of tenofovir amibufenamide (TMF) on blood lipid profiles in
patients with chronic hepatitis B (CHB) remains unclear. This study aimed to explore …